Items Tagged ‘Stage IV (D)/Relapsed Colon Cancer’

June 20, 2013

Erbitux Plus FOLFIRI Outperforms Avastin Plus FOLFIRI for First-Line Treatment of Metastatic Colorectal Cancer

By

For the initial (first-line) treatment of metastatic colorectal cancer with no KRAS gene mutations, the combination of Erbitux® (cetuximab) and FOLFIRI chemotherapy was more effective than the combination of Avastin® (bevacizumab) and FOLFIRI. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology. Erbitux and Avastin are both targeted therapies that […]

View full entry

Tags: Colon Cancer, Stage IV (D)/Relapsed Colon Cancer


October 27, 2008

KRAS Affects Outcomes with Erbitux® in Colorectal Cancer

By

KRAS Affects Outcomes with Erbitux® in Colorectal Cancer The KRAS mutation affects survival among patients with colorectal cancer who are treated with Erbitux (cetuximab). These results were recently published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal cancer refers to […]

View full entry

Tags: Stage IV (D)/Relapsed Colon Cancer